• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthOpioid Crisis

DEA Whistleblower Blasts Drug Distributors, Congress Over Opioid ‘Collusion’

By
David Meyer
David Meyer
and
Geoffrey Smith
Geoffrey Smith
Down Arrow Button Icon
By
David Meyer
David Meyer
and
Geoffrey Smith
Geoffrey Smith
Down Arrow Button Icon
October 16, 2017, 9:29 AM ET

The U.S.’s biggest drug distributors and some of its most senior politicians colluded to fuel the country’s opioid epidemic, leading directly to thousands of unnecessary deaths.

That was the conclusion of a former Drug Enforcement Agency official whose blistering testimony was carried on last night’s edition of 60 Minutes on CBS and in the Washington Post, which also participated in the investigation.

“This is an industry that’s out of control. If they don’t follow the law in drug supply, and diversion occurs, people die. That’s just it, people die,” Joe Rannazzisi, the former DEA agent turned whistleblower, told CBS. He’s now advising lawyers suing the opioid industry.

Rannazzisi singled out the country’s three biggest drug distribution companies for criticism: Cardinal Health (CAH), McKesson (MCK) and AmerisourceBergen (ABC). Together the three account for almost 90 percent of their market, he explained.

Read: Cigna Escalates War on Opioids With OxyContin Crackdown. Is It About Public Health or Business?

Bill Whitaker said he was implying that “these big companies knew that they were pumping drugs into American communities that were killing people.”

“That’s not an implication, that’s a fact,” Rannazzisi replied. “That’s exactly what they did…This is an industry that allowed millions and millions of drugs to go into bad pharmacies and doctors’ offices that distributed them out to people who had no legitimate need for those drugs.”

McKesson didn’t respond immediately to the allegations. Cardinal issued a statement saying that: “Our people care deeply about this issue and the devastation it has caused American families and communities. We will continue to work alongside regulators, manufacturers, prescribers, pharmacists, educators, patients and others to fight opioid abuse and addiction.” (For the full statement, click here).

AmerisourceBergen CEO Steve Collis argued in a recent blog post that distributors merely execute what is demanded from pharmacies and approved by the DEA.

“We report the quantity and details of every order of opioid-based medication we ship directly to the DEA on a daily basis,” Collis wrote. “We use complex algorithms to identify and stop orders that are deemed to be suspicious. In fact, we’ve reported and stopped tens of thousands of suspicious orders since 2007, not to mention the countless other orders that pharmacies never had the opportunity to place because we declined to service them altogether.”

The Healthcare Distribution Alliance, an industry lobby group, meanwhile argued in a statement that it had been raising concerns about prescription of painkillers for years but the DEA had failed to respond.

“Our industry has continuously sought opportunities to communicate and coordinate more effectively with DEA to better understand our reporting responsibilities under the Controlled Substances Act, and to work together to mitigate the opioid epidemic,” the HDA said. “Prior to 2016, these efforts were not reciprocated — as noted by the Government Accountability Office (GAO) in a July 2015 report.”

Read: Big Pharma Is Getting Hit With a Huge Wave of Opioid Suits

A law signed by then-president Barack Obama last year made it much more difficult for the Drug Enforcement Agency (DEA) to crack down on the illegal distribution and sale of prescription painkillers such as Vicodin and oxycodone, the investigation found.

The law in question, the Ensuring Patient Access and Effective Drug Enforcement Act, was championed by Republican congressman Tom Marino and—according to the story—largely written by D. Linden Barber, a former DEA lawyer who went on to work for the drug companies. Marino is currently Donald Trump’s pick to head the Office of National Drug Control Policy.

The law was supposed to aid enforcement by improving ties with industry. However, it made a crucial change to the standard required for the DEA to freeze drug shipments that it suspected were finding their way to addicts in opioid-ravaged communities. For four decades, the DEA could freeze shipments that posed an “imminent danger,” but the law changed that to “a substantial likelihood of an immediate threat.”

Read: As America’s Opioid Crisis Spirals, Giant Drug Distributor McKesson Is Feeling the Pain

The Washington Post noted that, in a draft article written for the Marquette Law Review, DEA chief administrative law judge John Mulrooney said the law “imposed a dramatic diminution of the agency’s authority” that made it “all but logically impossible” to stop a drug company distributing its wares for non-compliance with federal law.

According to the article, the White House did not appreciate the impact of the change when Obama signed the law. However, despite the fact that the opioid epidemic has reached the level of “national emergency,” not one order has been made against a distributor or manufacturer since late 2015.

The Post said it is currently suing the Justice Department to get its hands on public records that might clarify what happened.

The DEA said Monday that it was doing everything it could to fight the opioid epidemic. “During the past seven years, we have removed approximately 900 registrations annually, preventing reckless doctors and rogue businesses from making an already troubling problem worse,” it said in a statement. CBS also reported that the Justice Department did not dispute any of the 60 Minutes story.

UPDATE: This article has been updated to include comment from AmerisourceBergen and the HDA.

About the Authors
By David Meyer
LinkedIn icon
See full bioRight Arrow Button Icon
By Geoffrey Smith
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

wyle
CommentaryTV
What HBO’s ‘The Pitt’ gets right—and wrong—about treating alcohol use disorder
By Jonathan Hunt-GlassmanApril 2, 2026
8 hours ago
cancer
HealthCancer
Cancer’s grim calculus for the young: their insurance status can determine how long they survive
By Rhonda Winegar, Tara Martin, Zhaoli Liu and The ConversationApril 1, 2026
1 day ago
Hungryroot Review 2026: What We Like About This Unique Meal Delivery
Healthmeal delivery
Hungryroot Review 2026: What We Like About This Unique Meal Delivery
By Emily PharesApril 1, 2026
1 day ago
Nutrafol Review 2026: Ingredients, Cost, and Whether It Works
HealthDietary Supplements
Nutrafol Review 2026: Ingredients, Cost, and Whether It Works
By Christina SnyderApril 1, 2026
1 day ago
gen z
CommentaryGen Z
Gen Z is engineering an analog future — and it’s at least a $5 billion opportunity
By Luba KassovaApril 1, 2026
2 days ago
sheryl
HealthLean In
Sheryl Sandberg tapped a 25-year-old to run Lean In. Here’s her plan to close the AI gender gap
By Jacqueline MunisApril 1, 2026
2 days ago

Most Popular

Gen Z fled San Francisco for Texas and Florida. Now they’re turning ‘welcomer cities’ into the next big tech towns
Real Estate
Gen Z fled San Francisco for Texas and Florida. Now they’re turning ‘welcomer cities’ into the next big tech towns
By Fortune EditorsApril 2, 2026
14 hours ago
Current price of gold as of April 1, 2026
Personal Finance
Current price of gold as of April 1, 2026
By Fortune EditorsApril 1, 2026
1 day ago
Two-thirds of parents say their adult Gen Z kids still rely on them financially  for support—even though it's putting them under strain
Success
Two-thirds of parents say their adult Gen Z kids still rely on them financially  for support—even though it's putting them under strain
By Fortune EditorsMarch 31, 2026
2 days ago
Current price of oil as of April 1, 2026
Personal Finance
Current price of oil as of April 1, 2026
By Fortune EditorsApril 1, 2026
1 day ago
The tax escape map: Billionaires are bolting for Florida from the West Coast and taking billions in tax revenue with them
Real Estate
The tax escape map: Billionaires are bolting for Florida from the West Coast and taking billions in tax revenue with them
By Fortune EditorsApril 2, 2026
15 hours ago
Deutsche Bank asked AI if it’s true that AI will solve the economy’s inflation problems. The robots answered
Economy
Deutsche Bank asked AI if it’s true that AI will solve the economy’s inflation problems. The robots answered
By Fortune EditorsApril 1, 2026
1 day ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.